Controlled human infection with Bordetella pertussis induces asymptomatic, immunising colonisation.
Bordetella pertussis is one of the leading causes of vaccine preventable death and morbidity globally. Human asymptomatic carriage as a reservoir for community transmission of infection might be a target of future vaccine strategies but has not been demonstrated to occur. To demonstrate that asymptomatic nasopharyngeal carriage of Bordetella pertussis is inducible in humans and to define microbiological and immunological features of pre-symptomatic infection. Healthy subjects aged 18-45 years with an anti-pertussis toxin IgG concentration of <20 IU/ml were inoculated intranasally with non-attenuated, wild type Bordetella pertussis strain B1917. Safety, colonisation and shedding were monitored over 17 days in an in-patient facility. Colonisation was assessed by culture and qPCR. Azithromycin was administered from day 14. The inoculum dose was escalated aiming to colonise at least 70% of participants. Immunological responses were measured. 34 participants were challenged in groups of four or five. The dose was gradually escalated from 103 colony forming units (0% colonised) to 105 colony forming units (80% colonised). Minor symptoms were reported in a minority of participants. Azithromycin eradicated colonisation in 48 hours in 88% of colonised individuals. Anti-pertussis toxin IgG seroconversion occurred in nine out of 19 colonised participants and in none of the participants who were not colonised. Nasal wash was a more sensitive method to detect colonisation than pernasal swabs. No shedding of Bordetella pertussis was detected in systematically collected environmental samples. Bordetella pertussis colonisation can be deliberately induced and leads to a systemic immune response without causing pertussis symptoms.ClinicalTrials.gov:NCT03751514.